Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007383 | Intermittent Claudication NIH | 1.00 |
| D016491 | Peripheral Vascular Diseases NIH | 0.58 |
| D058729 | Peripheral Arterial Disease NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0004417 | Intermittent claudication HPO | 1.00 |
| HP:0004950 | Peripheral arterial stenosis HPO | 0.38 |
Navigate: Correlations HPO
There is one clinical trial.
Intermittent claudication is the most common manifestation of peripheral arterial disease, a common cardiovascular disease that causes blocked blood vessels (arteries) in the leg. Symptoms consist of persistent pain in one or both legs during exercise that is relieved with rest. Evidence suggests that high levels of uninterrupted sitting and sedentary behaviour are associated with cardiovascular disease risk, mortality and all-cause mortality. One of the main goals for treating people with intermittent claudication, is increased participation in physical activity. Supervised Exercise Programmes are recommended however these are not well tolerated and compliance is low. Alternative exercise, including short bouts of physical activity to break up sedentary time, has been suggested to help improve physical function. This study will investigate whether alternative exercise, in the form of breaking up prolonged sitting time, will improve physical function in patients with intermittent claudication. A suite of multi-modal activities will be developed offering a variety of exercise activities which will inform a personalised activity plan for each participant. Patients will be screened during their routine clinic appointment at Glenfield Hospital. All other study activity will take place in a laboratory within the Leicester Diabetes Centre at the Leicester General Hospital (LGH). Patients will be expected to attend LGH for up to a maximum of 4 visits where study data will be collected from performing physical measurements and assessments, and the completion of various questionnaires. Additional data will be collected from activity monitors which will be worn for up to 8 days at baseline and follow-up, measuring step count and time, inactivity, activity time and intensity, and sleep duration. Participants will also be expected to wear activity monitors for the duration of the 8-week intervention to measure steps. Participants will be in the study for approximately 18 weeks in total.
Description: Measured using accelerometers (comparison of time spent sitting at baseline vs. follow-up assessed via acceleration)
Measure: To investigate overall changes in sitting time Time: 8 weeksDescription: Total score for 16 questions measuring walking distance, speed and stair climbing from 0 (worst/inability) to 4 (best/without limitations)
Measure: The walking impairment questionnaire Time: 8 weeksDescription: Measured using accelerometers (comparison of time spent performing physical activity at baseline vs. follow up assessed via mean acceleration mg/day )
Measure: To investigate overall changes in time spent performing physical activity Time: 8 weeksDescription: Measured using accelerometers (comparison of time spent in light physical activity at baseline vs. follow up assessed via acceleration mins/day)
Measure: To investigate overall changes in time spent in light physical activity Time: 8 weeksDescription: Measured using accelerometers (comparison of time spent in moderate physical activity at baseline vs. follow up assessed via acceleration mins/day)
Measure: To investigate overall changes in time spent in moderate physical activity Time: 8 weeksDescription: Measured using accelerometers (comparison of time spent in vigorous physical activity at baseline vs. follow up assessed via acceleration mins/day)
Measure: To investigate overall changes in time spent in vigorous physical activity Time: 8 weeksDescription: Measured using accelerometers (comparison of time spent sitting at baseline vs. follow-up assessed via acceleration)
Measure: To investigate overall changes in time spent in prolonged sitting Time: 8 weeksDescription: Measured using accelerometers (comparison of time spent sleeping at baseline vs. follow-up assessed via acceleration)
Measure: To investigate overall changes in time spent in sleep Time: 8 weeksDescription: Measured using the Vascular Quality of Life (VascuQoL) questionnaire
Measure: To investigate whether personalised activity breaks in sitting time improve quality of life Time: 8 weeksDescription: Measured using the Euro Quality of Life (EQ-5D-5L) questionnaire
Measure: To investigate whether personalised activity breaks in sitting time improve quality of life Time: 8 weeksDescription: Measured using the modified medical research council (mMRC) dyspnoea scale
Measure: To investigate whether personalised activity breaks in sitting time improve breathlessness Time: 8 weeksDescription: Measured using Chalder's Fatigue Scale
Measure: To investigate whether personalised activity breaks in sitting time improve fatigue Time: 8 weeksDescription: Measured using the hospital anxiety and depression scale
Measure: To investigate whether personalised activity breaks in sitting time improve anxiety and depression Time: 8 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports